Diarrhea-predominant irritable bowel syndrome
Conditions
Interventions
1st step Administration of ramosetron hydrochloride 5 microgram once a day for 4 weeks.
2nd step : increase Administration of ramosetron hydrochloride 10 microgram once a day for 8 weeks. 2nd ste
Sponsors
Shimane University Faculty of Medicine, Department of Gastroenterology and Hepatology
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) At least 1 question with grade 4 or higher scores in questions 11, 12, and 14. 2) Subjects with written informed consent
Exclusion criteria
Exclusion criteria: 1) Patients who have bowel move disturbance by organic lesion such as IBD (UC and Crohn disease etc.) and cancer. 2) Patients suspected of obstruction in stomach and intestines, and with a history of total gastric resection or bowel resection but not appendectomy 3) Patients with serious complications (liver, kidney, heart, lung, circulatory, or metabolic disorder) 4) Patients with a history of drug allergy 5) Others, including patients who are unfit for the study as determined by the attending doctor 6) Patients who are taking polycarbophil calcium.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of ramosetron hydrochloride in patients with diarrhea-predominant irritable bowel syndrome (Indicator: GSRS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Reliability and validity of the Izumo scale in the monitoring of symptoms in patients with irritable bowel syndrome | — |
Countries
Japan
Outcome results
None listed